MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Search

Smith & Nephew PLC ADR

Uždarymo kaina

33.49 1.24

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

33.11

Max

33.89

Pagrindiniai rodikliai

By Trading Economics

Pajamos

35M

331M

Pardavimai

203M

3.2B

P/E

Sektoriaus vid.

22.818

66.418

Dividendų pajamingumas

2.43

Pelno marža

10.368

Darbuotojai

16,988

EBITDA

133M

856M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+5.52% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

2.43%

2.36%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.3B

14B

Ankstesnė atidarymo kaina

32.25

Ankstesnė uždarymo kaina

33.49

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Smith & Nephew PLC ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-10 17:04; UTC

Pagrindinės rinkos jėgos

FDA Rejects Replimune's Melanoma Drug for a Second Time

2026-04-11 00:00; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Big Yachts, Big Bucks -- Barrons.com

2026-04-10 21:55; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

2026-04-10 21:01; UTC

Uždarbis

Cango Inc.: Files Annual Report on Form 20-F With SEC

2026-04-10 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-04-10 20:50; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-04-10 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-04-10 20:31; UTC

Rinkos pokalbiai

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

2026-04-10 20:10; UTC

Įsigijimai, susijungimai, perėmimai

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

2026-04-10 19:15; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-04-10 19:15; UTC

Rinkos pokalbiai

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

2026-04-10 19:08; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-10 19:08; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures End Week Lower -- Market Talk

2026-04-10 18:38; UTC

Rinkos pokalbiai

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

2026-04-10 18:25; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Precious Metals Finish With Weekly Gains -- Market Talk

2026-04-10 18:05; UTC

Rinkos pokalbiai

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

2026-04-10 17:31; UTC

Rinkos pokalbiai
Svarbiausios naujienos

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

2026-04-10 17:26; UTC

Uždarbis

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

2026-04-10 17:10; UTC

Rinkos pokalbiai

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

2026-04-10 17:00; UTC

Svarbiausios naujienos

Construction Business Taking a Hit From Iran Conflict -- WSJ

2026-04-10 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-04-10 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-10 16:12; UTC

Uždarbis

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

2026-04-10 16:11; UTC

Uždarbis

Partners Group: Traditional Programs Contributed $3.3B

2026-04-10 16:10; UTC

Uždarbis

Partners Group: $5B of New Commitments Came From Bespoke Solutions

2026-04-10 16:10; UTC

Uždarbis

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

2026-04-10 16:10; UTC

Uždarbis

Partners Group 1Q New Client Demand $8.3B

2026-04-10 16:09; UTC

Uždarbis

Partners Group Continued to See Positive Fundraising Momentum in 1Q

2026-04-10 15:54; UTC

Įsigijimai, susijungimai, perėmimai

Plenitude Completes Acquisition of Acea Energia

2026-04-10 15:38; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Smith & Nephew PLC ADR Prognozė

Kainos tikslas

By TipRanks

5.52% į viršų

12 mėnesių prognozė

Vidutinis 34.96 USD  5.52%

Aukščiausias 35 USD

Žemiausias 34.91 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Smith & Nephew PLC ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

2 ratings

0

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

26.64 / 28.37Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat